Eli Lilly and Company (NYSE:LLY) Shares Bought by Goldstone Financial Group LLC

Goldstone Financial Group LLC increased its holdings in Eli Lilly and Company (NYSE:LLY) by 43.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 420 shares of the company’s stock after purchasing an additional 127 shares during the period. Goldstone Financial Group LLC’s holdings in Eli Lilly and Company were worth $324,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in LLY. Channel Wealth LLC boosted its position in shares of Eli Lilly and Company by 11.4% in the fourth quarter. Channel Wealth LLC now owns 8,504 shares of the company’s stock worth $6,565,000 after acquiring an additional 870 shares during the last quarter. Capital Planning LLC boosted its holdings in shares of Eli Lilly and Company by 15.6% in the 4th quarter. Capital Planning LLC now owns 481 shares of the company’s stock valued at $371,000 after purchasing an additional 65 shares during the last quarter. KMG Fiduciary Partners LLC boosted its holdings in shares of Eli Lilly and Company by 3.3% in the 4th quarter. KMG Fiduciary Partners LLC now owns 26,361 shares of the company’s stock valued at $20,350,000 after purchasing an additional 831 shares during the last quarter. Decker Retirement Planning Inc. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $189,000. Finally, Occidental Asset Management LLC increased its holdings in shares of Eli Lilly and Company by 1.2% during the 4th quarter. Occidental Asset Management LLC now owns 1,475 shares of the company’s stock worth $1,139,000 after buying an additional 18 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 4.1 %

LLY opened at $726.24 on Friday. Eli Lilly and Company has a 12-month low of $612.70 and a 12-month high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The stock has a market capitalization of $689.43 billion, a PE ratio of 78.51, a P/E/G ratio of 1.66 and a beta of 0.41. The firm’s fifty day moving average price is $783.25 and its 200 day moving average price is $856.02.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The company had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.10 EPS. As a group, research analysts expect that Eli Lilly and Company will post 13.14 EPS for the current fiscal year.

Eli Lilly and Company declared that its board has approved a stock buyback plan on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a $1.50 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.83%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of research reports. Citigroup boosted their price target on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Sanford C. Bernstein started coverage on shares of Eli Lilly and Company in a research report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price target on the stock. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, January 1st. Finally, Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Four research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,002.22.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.